

How loss of single gene fuels deadly childhood brain cancer

10 September 2020



Credit: CC0 Public Domain

Atypical teratoid rhabdoid tumors (ATRT) are a rare, fast-growing form of brain cancer that usually strikes children three years and younger, though they can occur in older children and adults. There are multiple treatments, but no definitive standard of care and long-term survival is poor.

The cause of ATRT is primarily linked to inactivation of a gene called SMARCB1, part of a larger complex that helps regulate <u>gene expression</u> and developmental processes. In a study published online September 10, 2020 in the journal *Genes & Development*, an international team of scientists, led by researchers at University of California San Diego School of Medicine and the San Diego Branch of the Ludwig Institute for Cancer Research, describe how the loss of the gene negatively impacts neural development and promotes tumor growth.

"Previous research has established that, unlike some cancers, ATRT is predominantly associated with the functional loss of a single gene—SMARCB1—which leads to tumor development through changes in how <u>genes</u> are expressed rather than the combined effect of multiple gene mutations," said senior author Frank Furnari, Ph.D., professor of pathology and Ludwig San Diego member.

"ATRT is a very deadly cancer with very few effective therapies, which are complicated by the negative effects of radiation upon the child's cognitive development. We need targeted therapeutics and to create those, we need to better understand the mechanisms driving ATRT."

Led by Furnari and first author Alison Parisian, a <u>graduate student</u> in Funari's lab, the team prompted the loss of SMARCB1 in human induced <u>pluripotent</u> <u>stem cells</u>, then directed the iPSCs to develop into neurons or into cerebral organoids—complexes of diverse nerve cells and glia that mimic functional aspects of the developing brain in miniature.

In doing so, they identified an interaction between the loss of SMARCB1 and neural differentiation pressure, which resulted in both a resistance to final differentiation and a defect in maintaining normal cell health that showed similarity to patient tumors.

"With this new information in hand," said Parisian, "our plan is to use our ATRT model and look for therapeutic targets that will cause these tumors to fully differentiate and therefore stop growing, which could prove to be an effective future therapy for ATRT."

More information: Alison D. Parisian et al, SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability, *Genes & Development* (2020). <u>DOI:</u> <u>10.1101/gad.339978.120</u>

Provided by University of California - San Diego



APA citation: How loss of single gene fuels deadly childhood brain cancer (2020, September 10) retrieved 11 October 2022 from <u>https://medicalxpress.com/news/2020-09-loss-gene-fuels-deadly-childhood.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.